Paxlovid’s Slow, Targeted Rollout Leaves Vulnerable Populations at Risk

Professor Brook Baker ’76 welcomes the Biden administration’s plans to expand access to Paxlovid, the first medication developed to treat COVID-19. However, “that still leaves a lot of people uncovered who aren’t near those kinds of facilities,” he says.